Novartis AG’s injectable brolucizumab for treating wet age-related macular degeneration and Celgene Corp./Agios Pharmaceuticals Inc.'s orphan drug enasidenib for acute myeloid leukemia could this week be recommended for approval across the EU.
A third new treatment – Merck & Co. Inc.'s combination antibacterial comprising imipenem, cilastatin and relebactam for infections due...